Outcomes Research in Review

Cardioprotective Effect of Metformin in Patients with Decreased Renal Function


 

References

Applications for Clinical Practice

The current study demonstrated that metformin use, as compared to sulfonylureas, has a lower risk of fatal or nonfatal major adverse cardiovascular events among patients with reduced kidney function. When clinicians are managing hyperglycemia in patients with type 2 diabetes, it is important to keep in mind that all medications have adverse effects. There are now 11 drug classes for treating diabetes, in addition to multiple insulin options, and the challenge for clinicians is to present clear information to guide patients using shared decision making, based on each patient’s clinical circumstances and preferences, to achieve individualized glycemic target ranges.

–Ka Ming Gordon Ngai, MD, MPH

Pages

Recommended Reading

FDA panel supports Vascepa expanded indication for CVD reduction
Journal of Clinical Outcomes Management
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
Journal of Clinical Outcomes Management
ISCHEMIA trial hailed as practice changing
Journal of Clinical Outcomes Management
GALILEO, GALILEO 4D: Mixed results in post-TAVR anticoagulation
Journal of Clinical Outcomes Management
Data build on cardiovascular disease risk after GDM, HDP
Journal of Clinical Outcomes Management
Evidence builds for AFib ablation’s efficacy in heart failure
Journal of Clinical Outcomes Management
Treating LDL to below 70 reduces recurrent stroke
Journal of Clinical Outcomes Management
Differences in U.S. and European aneurysm guidelines called unavoidable
Journal of Clinical Outcomes Management
Large population-based study underscores link between gout, CVD event risk
Journal of Clinical Outcomes Management
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
Journal of Clinical Outcomes Management